|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.12.25 - 15:03
|
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS), multiple real world studies on the burden of depression and anti-seizure medication (ASM) titration in epilepsy, and new data for its pre-clinical program in Dravet syndrome. These data are being presented at the American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 in Atlanta, Georgia....
|
|
|
|
|
|
|
|
|
|
|
|
|
29.10.25 - 07:54
|
ASM International NV Q3 Income Climbs (AFX)
|
|
|
ALMERE (dpa-AFX) - ASM International NV (ASM.AS) released a profit for its third quarter that Increased, from last yearThe company's earnings totaled EUR384.2 million, or EUR7.82 per share. This c......
|
|
|
|
|
|
|
|
|
28.10.25 - 20:36
|
ASM International NV Profit Advances In Q3 (AFX)
|
|
|
ALMERE (dpa-AFX) - ASM International NV (ASM.AS) announced earnings for its third quarter that Increased, from the same period last yearThe company's earnings totaled EUR384.1 million, or EUR7.82 ......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
